Marker Therapeutics (MRKR) said Thursday it has agreed to sell securities worth $16.1 million to investors including Blue Owl Healthcare Opportunities (OWL), New Enterprise Associates and Aisling Capital in a private placement.
Marker said it will sell about 5 million shares, or pre-funded warrants, and warrants to buy up to around 5 million shares at a price of $3.20 per share and accompanying warrant.
Net proceeds will be allocated toward supporting the phase 1 Apollo trial studying the company's multi-antigen recognizing T cell product, it added.
The company's shares were down 4.2% in recent trading.
Price: 3.81, Change: -0.22, Percent Change: -5.46
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。